Wednesday, 26 August 2026European Markets

AIRTHINGS Stock Over 16% Down In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of AIRTHINGS (Oslo Børs All-share Index_GI: AIRX.OL) dropped by a staggering 16.62% in 5 sessions from 3.73 kr to 3.11 kr at 01:36 EST on Monday, after three sequential sessions in a row of gains. Oslo Børs All-share Index_GI is jumping 0.37% to 1,418.24 kr, after three sequential sessions in a row of losses.

About AIRTHINGS

Airthings ASA, together with its subsidiaries, engages in the manufacture and sale of air quality sensors and hardware-enabled software products for air quality, radon measurement, and energy efficiency solutions worldwide. The company operates through three segments: Consumer, Business, and Professional segments. It offers digital radon detectors, as well as smart indoor air quality monitors and solutions for professionals, homes, schools, offices, and other commercial buildings. The company provides its products under the View Plus, Wave Plus, Wave Radon, Wave Mini, House Kit, Hub, Corentium Home, Plus, and Pro brands. It also serves homeowners, businesses, and professionals. The company was incorporated in 2008 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, AIRTHINGS has a trailing twelve months EPS of -0.3 kr.

Volume

Today's last reported volume for AIRTHINGS is 2145112 which is 767.99% above its average volume of 229846.

More news about AIRTHINGS (AIRX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com